Literature DB >> 10681365

Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.

D Hardy1, D Amsterdam, L A Mandell, C Rotstein.   

Abstract

The in vitro activity of gemifloxacin against 316 bloodstream isolates of staphylococci, pneumococci, and enterococci was compared with the activities of six fluoroquinolones and three other antimicrobial agents. Of the antimicrobial agents tested, gemifloxacin was the most potent against penicillin-intermediate and -resistant pneumococci, methicillin-susceptible and -resistant Staphylococcus epidermidis isolates, and coagulase-negative staphylococci.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10681365      PMCID： PMC89773          DOI： 10.1128/AAC.44.3.802-805.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Surveillance for penicillin-nonsusceptible Streptococcus pneumoniae--New York City, 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-04-11       Impact factor: 17.586

2.  A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens.

Authors:  R J Davidson; D E Low
Journal:  Can J Infect Dis       Date:  1999-03

Review 3.  Vancomycin-resistant enterococci. Mechanism and clinical relevance.

Authors:  G M Eliopoulos
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

4.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America.

Authors:  J G Bartlett; R F Breiman; L A Mandell; T M File
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

5.  Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

Authors:  M G Cormican; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance.

Authors:  M C Maranan; B Moreira; S Boyle-Vavra; R S Daum
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

7.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

8.  Emergence and nosocomial transmission of ampicillin-resistant enterococci.

Authors:  J M Boyce; S M Opal; G Potter-Bynoe; R G LaForge; M J Zervos; G Furtado; G Victor; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191
  8 in total
  10 in total

Review 1.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 2.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Gemifloxacin.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

5.  A Combination of Pharmacophore-Based Virtual Screening, Structure-Based Lead Optimization, and DFT Study for the Identification of S. epidermidis TcaR Inhibitors.

Authors:  Srimai Vuppala; Jaeyoung Kim; Bo-Sun Joo; Ji-Myung Choi; Joonkyung Jang
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 6.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

9.  History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.

Authors:  Joseph F John; Alexander M Harvin
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

10.  Changes in bacterial population of gastrointestinal tract of weaned pigs fed with different additives.

Authors:  Mercè Roca; Miquel Nofrarías; Natàlia Majó; Ana María Pérez de Rozas; Joaquim Segalés; Marisol Castillo; Susana María Martín-Orúe; Anna Espinal; Joan Pujols; Ignacio Badiola
Journal:  Biomed Res Int       Date:  2014-01-19       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.